Skip to main content

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves’ disease will be presented.

Late-Breaking Oral Presentation Details:

Title:Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves’ Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study
Presentation:#0020
Session:#5 – Autoimmune Thyroid Disease
Date and Time:Friday, November 1, 2024, 4:05pm – 5:05pm ET
Presenter:George Kahaly, MD, PhD
  

About Graves’ disease

Graves’ disease is an autoimmune disorder associated with the overproduction of thyroid hormones and is the most common cause of hyperthyroidism. Although Graves’ disease can affect any age group or gender, it occurs often in women younger than 40 years of age. In Graves’ disease, harmful IgG autoantibodies bind to and activate the thyroid-stimulating hormone receptor present on the thyroid gland, stimulating excess thyroid hormone production. Existing treatments, which include antithyroid drugs, radioactive iodine, and thyroid surgery, are aimed at reducing thyroid hormone levels to lessen the severity of symptoms. These treatments have remained largely unchanged for the past 70 years.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com

Source: Immunovant, Inc.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.